FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy
The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.
Looking to the Future of Independent Pharmacy
Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.
Lumateperone Demonstrates Efficacy in Reducing Symptomatic Relapse Risk in Schizophrenia
The drug is also approved to treat schizophrenia and bipolar depression.
Podcast: Pharmacy Financing With First Financial Bank
Learn more about the ins and outs of pharmacy ownership from the experts at First Financial Bank.
FDA Expands OA REMS, Mandates Mail-Back Envelopes for Opioid Analgesics
The FDA has mandated that companies participating in the Opioid Analgesic Risk Evaluation and Mitigation Strategy program provide pre-paid mail-back envelopes for unused or expired opioid medications.
FDA Roundup: Agency Highlights from October 2024
Check out these important FDA updates from the month of October 2024.
